Ricevi le ultime notizie sulle azioni Opthea con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di OPT

Ultime notizie per

OPTHEA LTD-SPON ADR

Opthea

Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.

Opthea Limited - American Depositary Shares

Opthea Ltd

Ocean Power Technologies, Inc. Common Stock

Ocean Power Technologies Inc

OPTEC INTERNATIONAL INC by Optec International, Inc.

Optec International Inc

Syntec Optics Holdings, Inc. - Class A Common Stock

Syntec Optics Holdings Inc

OPTIMI HEALTH CORP by OPTIMI HEALTH CORP.

Optimi Health Corp

Optimize Strategy Index ETF

Opus - United States Dollar

OPTIBIOTIX HEALTH PLC by OPTIBIOTIX HEALTH PLC

OptiBiotix Health PLC

OPTIMUS GROUP CO LTD. by OPTIMUS GROUP CO LTD.

Optimus Group Co Ltd

OPTIMUM INTRACTVE USA NEW by Optimum Interactive USA Ltd.

Optimum Interactive USA Ltd

OptiNose Inc COM NEW

News

Press Releases

Opthea to Host Investor Days in New York and Australia

Opthea Wet AMD Data Featured at Macula Society Meeting

Opthea to Present at Oppenheimer Healthcare Conference

Health Care

Opthea Completes COAST Final Week 52 Patient Visit

Opthea Completes Drug Product PPQ Campaign

Earnings

Opthea Reports Half Year Results and Business Updates

Analyst Ratings

General

Opthea Announces Phase 2b Wet AMD Publication

Opthea Announces COAST Phase 3 Trial Topline Results

Opthea Announces Decision to Discontinue Wet AMD Trials

Opthea Provides Corporate Update

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

Opthea Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO